JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis
Status:
Unknown status
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation (HSCT)
in patients with primary or secondary myelofibrosis : a prospective phase II